Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	Phase 1 <br/ >Number of patients with one or more unexpected serious adverse event(s) (SAEs) considered by the investigator to be related to study drug administration <br/ > <br/ >Phase 2 <br/ >Proportion (percent) of patients turning COVID-19 negative Day 5 and Day 7Timepoint: Phase 1 <br/ >Baseline through Day 28 <br/ > <br/ >Phase 2 <br/ >Day 5 and Day 7	Phase 1 <br/ >Number of patients with one or more unexpected serious adverse event(s) (SAEs) considered by the investigator to be related to study drug administration <br/ > <br/ >Phase 2 <br/ >Proportion (percent) of patients turning COVID-19 negative Day 5 and Day 7Timepoint: Phase 1 <br/ >Baseline through Day 28 <br/ > <br/ >Phase 2 <br/ >Day 5 and Day 7
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
March 26, 2021, 2:21 p.m.	oms	Phase 1 <br/ >Number of patients with one or more unexpected serious adverse event(s) (SAEs) considered by the investigator to be related to study drug administration <br/ > <br/ >Phase 2 <br/ >Proportion (percent) of patients turning COVID-19 negative Day 5 and Day 7Timepoint: Phase 1 <br/ >Baseline through Day 28 <br/ > <br/ >Phase 2 <br/ >Day 5 and Day 7	Phase 1 <br/ >Number of patients with one or more unexpected serious adverse event(s) (SAEs) considered by the investigator to be related to study drug administration <br/ > <br/ >Phase 2 <br/ >Proportion (percent) of patients turning COVID-19 negative Day 5 and Day 7Timepoint: Phase 1 <br/ >Baseline through Day 28 <br/ > <br/ >Phase 2 <br/ >Day 5 and Day 7